Results 251 to 260 of about 499,895 (395)
The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
European Journal of Heart Failure, EarlyView.Abstract
This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes‐Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats +20 morewiley +1 more sourceFinerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial
European Journal of Heart Failure, EarlyView.Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims
The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray +18 morewiley +1 more sourceMavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, 2020 I. Olivotto, A. Oreziak, R. Barriales-Villa, T. Abraham, A. Masri, P. García-Pavía, S. Saberi, N. Lakdawala, M. Wheeler, A. Owens, M. Kubanek, W. Wojakowski, M. Jensen, J. Gimeno-Blanes, K. Afshar, J. Myers, Sheila M. Hegde, S. Solomon, A. Sehnert, David X. Zhang, Wanying Li, Mondira Bhattacharya, J. Edelberg, C. Waldman, S. Lester, Andrew Wang, Carolyn Y. Ho, D. Jacoby, J. Bartunek, A. Bondue, E. V. Craenenbroeck, D. Zemánek, M. Jensen, J. Mogensen, J. Thune, P. Charron, A. Hagège, O. Lairez, J. Trochu, C. Axthelm, H. Duengen, N. Frey, V. Mitrović, M. Preusch, J. Schulz-Menger, T. Seidler, M. Arad, M. Halabi, A. Katz, D. Monakier, Offir Paz, S. Viskin, D. Zwas, H. Rocca, M. Michels, D. Dudek, Z. Oko-Sarnowska, N. Cardim, H. Pereira, P. G. Pavía, J. G. Blanes, R. H. Urbano, Luis Miguel Rincón Diaz, P. Elliott, Z. Yousef, T. Abraham, P. Alvarez, R. Bach, R. Becker, L. Choudhury, D. Fermin, J. Jefferies, Christopher Kramer, N. Lakdawala, S. Lester, A. Marian, Mathew Maurer, S. Nagueh, David Owens, F. Rader, M. Sherrid, J. Shirani, J. Symanski, A. Turer, O. Wever-Pinzon, M. Wheeler, T. Wong, M. Yamani +87 moresemanticscholar +1 more sourceFinerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial
European Journal of Heart Failure, EarlyView.The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray +16 morewiley +1 more sourceThe efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF
European Journal of Heart Failure, EarlyView.Effect of finerenone on a hierarchical endpoint. CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure. ABSTRACT Aims
FINEARTS‐HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and ...Toru Kondo, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Meike Brinker, James Lay‐Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern‐En Chiang, Gerasimos Filippatos, Carolyn S.P. Lam, Mark C. Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A. Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V McMurray +23 morewiley +1 more source